Enteric-coated mycophenolate sodium for transplant immunosuppression

American Journal of Health-System Pharmacy

Volumn 62, Issue 21, 2005, Pages 2252-2259

  Ingle, Gordon R ^a,b   Shah, Tariq ^a,c,d  

^a National Institute of Transplantation Los Angeles   (United States)

^b ROSEMAN UNIVERSITY OF HEALTH SCIENCES   (United States)

^c ST VINCENT MEDICAL CENTER   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Coatings; Dosage; Drug comparisons; Drug interactions; Drugs; Drugs, availability; Excretion; Half life; Immunosuppressive agents; Mechanism of action; Metabolism; Mycophenolate mofetil; Mycophenolate sodium; Mycophenolic acid glucuronide; Pharmacokinetics; Release

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ANEMIA; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; LEUKOPENIA; LIVER METABOLISM; LYMPHOMA; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN CANCER; SMALL INTESTINE; STOMACH; TREATMENT OUTCOME; URINARY TRACT INFECTION;

EID: 27644481319     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040380     Document Type: Review

References (41)

1. European Mycophenolate Mofetil Cooperative Study Group. A placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995; 345:1321-5.
2. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995; 60:225-32.
3. Mitsui A, Suzuki S. Immunosuppressive effect of mycophenolic acid. J Antibiot. 1969; 22:358-63.
4. Jackson RC, Weber G, Morris HP. IMP dehydrogenase, an enzyme linked with proliferation and malignancy. Nature. 1975; 256:331-3.
5. Allison AC, Kowalski WJ, Muller CD et al. Mechanisms of action of mycophenolic acid. Ann N Y Acad Sci 1993; 696:63-87.
6. Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev. 1993; 136:5-28.
7. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci. 1993; 685:309-29.
8. Nagai M, Natsumeda Y, Konno Y et al. Selective up-regulation of type II inosine 5′-monophosphate dehydrogenase messenger RNA expression in human leukemias. Cancer Res. 1991; 51:3886-90.
9. Carr SF, Papp E, Wu JC et al. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem. 1993; 268: 27286-90.
10. Natsumeda Y, Ohno S, Kawasaki H et al. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem. 1990; 265: 5292-5.
11. Konno Y, Natsumeda Y, Nagai M et al. Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines. J Biol Chem. 1991; 266:506-9.
12. Budde K, Glander P, Hahn U et al. Pharmacokinetic and pharmacodynamic comparison of mycophenolate mofetil and enteric-coated mycophenolate sodium in maintenance renal transplant patients. Am J Transplant. 2002; 2(suppl 3):399. Abstract.
13. Granger DK, ERLB 301 Renal Transplant Study Group, ERL B 302 Renal Transplant Study Group. Enteric-coated mycophenolate sodium: results of two pivotal global multicenter trials. Transplant. Proc. 2001; 33:3241-4.
14. Tedesco-Silva H, Bastien MC, Choi L et al. Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium (ec-mps, Myfortic). Am J Transplant. 2004; 4(suppl 8):250. Abstract.
15. Shaw LM, Korecka M, Venkataramanan R et al. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant. 2003; 3:534-42.
16. Myfortic (mycophenolate sodium delayed-release tablets) package insert. East Hanover, NJ: Novartis Pharmaceuticals; 2004 Feb.
17. Shaw LM, Korecka M, van Breeman R et al. Analysis, pharmacokinetics and therapeutic drug monitoring of mycophenolic acid. Clin Biochem. 1998; 31:323-8.
18. Schutz E, Shipkova M, Armstrong VW et al. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem. 1999; 45:419-22.
19. Shipkova M, Wieland E, Schutz E et al. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes. Transplant Proc. 2001; 33:1080-1.
20. Shipkova M, Armstrong VW, Wieland E et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol. 1999; 126:1075-82.
21. Wieland E, Shipkova M, Schellhaas U et al. Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects? Clin Biochem. 2000; 33:107-13.
22. Johnson HJ, Swan SK, Heim-Duthoy KL et al. The pharmacokinetics of a single oral dose of mycophenolate mofetil in patients with varying degrees of renal function. Clin Pharmacol Ther. 1998; 63:512-8.
23. Shaw LM, Mick R, Nowak I et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998;38:268-75.
24. Kaplan B, Meier-Kriesche HU, Friedman G et al. The effect of renal insufficiency on mycophenolic acid protein-binding. J Clin Pharmacol 1999; 39:715-20.
25. Parker G, Bullingham R, Kamm B et al. Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment. J Clin Pharmacol 1996; 36:332-44.
26. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit. 1999; 21:536-9.
27. Smak Gregoor PJ, van Gelder, T, Hesse CJ et al. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study. Nephrol Dial Transplant. 1999; 14:706-8.
28. Gregoor PJ, deSevaux RG, Hene RJ et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation. 1999; 68:1603-6.
29. Kaplan B, Bastien MC, Herwig-Ulf MK et al. Steady state pharmacokinetics of enteric-coated mycophenolate sodium (Myfortic) in stable renal transplant patients differ during concomitant treatment with neoral or tacrolimus. Am J Transplant. 2004; 4(suppl 8):230. Abstract.
30. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004; 4:231-6.
31. Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: results of a 1-year study. Am J Transplant. 2004; 4:237-43.
32. Nashan B, Ivens K, Suwelack B et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the Myfortic Prospective Multicenter Study. Transplant Proc. 2004; 36(2 suppl):521S-523S.
33. Abbud-Filho M, Giron F, Hernandez E et al. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: interim results of a multicenter Latin American study. Transplant Proc. 2004; 36:1647-9.
34. Chan L, Mulgaonkar S, Schiavelli R et al. Improved health related quality of life in renal transplant patients suffering from gastrointestinal complaints when converted from mycophenolate mofetil to enteric-coated mycophenolate sodium. Nephrology. 2005; 10(suppl):A215-6. Abstract.
35. Allison AC, Eugui EM. Preferential suppression of lymphocyte proliferation by mycophenolic acid and predicted long-term effects of mycophenolate mofetil in transplantation. Transplant Proc. 1994; 26:3205-10.
36. Sanquer S, Breil M, Baron C et al. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther. 1999; 65:640-8.
37. McCauley R, Kong SE, Hall J. Glutamine and nucleotide metabolism within enterocytes. J Parenter Enteral Nutr. 1998; 22:105-11.
38. Mourad M, Malaise J, Chaib Eddour D et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem. 2001; 47:88-94.
39. Mourad M, Wallemacq P, Konig J et al. Therapeutic monitoring of mycophenolate mofetil in organ transplant recipients: is it necessary? Clin Pharmacokinet. 2002; 41:319-27.
40. Shaw LM, Pawinski T, Korecka M et al. Monitoring of mycophenolic acid in clinical transplantation. Ther Drug Monit. 2002; 24:68-73.
41. Shaw LM, Holt DW, Oellerich M et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit. 2001; 23:305-15.